DGX Financials Quest Diagnostics

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 29 h ago Overview →

Growth & profitability

Revenue has grown 3.2% per year over the past 5 years.
Net income has grown slower than revenue (-7.1% vs 3.2% per year).
Operating margin has contracted, at 14.1% in the latest year.
Free cash flow has declined 3.1% per year over the past 5 years.

Financial health

Total debt ($5.7B) exceeds cash ($420M); net debt is $5.3B.
Total debt has grown faster than revenue (7.2% vs 3.2% per year).
Total debt is 2.7× EBITDA.

Shareholder returns

Dividends have been paid for 15 consecutive years, consuming 35.6% of earnings and 26.0% of free cash flow.
The dividend has grown 3.5% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$11.0B	$992M	33.2%	14.1%	$1.4B	$5.7B	$420M
2024	$9.9B	$871M	32.9%	13.6%	$909M	$6.2B	$549M
2023	$9.3B	$854M	33.0%	13.6%	$864M	$4.7B	$686M
2022	$9.9B	$946M	34.7%	14.4%	$1.3B	$4.0B	$315M
2021	$10.8B	$2.0B	39.0%	22.1%	$1.8B	$4.0B	$872M
2020	$9.4B	$1.4B	38.5%	20.9%	$1.6B	$4.0B	$1.2B
2019	$7.7B	$858M	34.8%	15.9%	$843M	$4.8B	$1.2B
2018	$7.5B	$736M	34.6%	14.6%	$817M	$3.9B	$135M
2017	$7.4B	$772M	36.2%	15.7%	$923M	$3.8B	$137M
2016	—	$645M	—	—	$823M	$3.7B	$359M
2015	—	$709M	—	—	$558M	$3.7B	$133M
2014	—	$556M	—	—	$636M	$3.7B	$192M
2013	—	$849M	—	—	$421M	$3.3B	$187M
2012	—	$556M	—	—	$1.0B	$3.4B	$296M
2011	—	$471M	—	—	$734M	$3.9B	$165M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Mar '26	$2.9B	$252M	32.5%	13.8%	$164M	—	$393M
Dec '25	$2.8B	$245M	32.4%	13.8%	$307M	$5.7B	$420M
Sep '25	$2.8B	$245M	33.7%	13.7%	$419M	—	$432M
Jun '25	$2.8B	$282M	34.2%	15.9%	$436M	—	$319M
Mar '25	$2.7B	$220M	32.5%	13.0%	$197M	—	$188M
Dec '24	$2.6B	$222M	32.7%	13.8%	$341M	$6.2B	$549M
Sep '24	$2.5B	$226M	32.6%	13.3%	$250M	$6.3B	$764M
Jun '24	$2.4B	$229M	33.5%	14.8%	$268M	—	$271M
Mar '24	$2.4B	$194M	32.6%	12.7%	$50M	—	$474M
Dec '23	$2.3B	$192M	32.2%	11.7%	$455M	$4.7B	$686M
Sep '23	$2.3B	$225M	32.9%	14.9%	$102M	—	$143M
Jun '23	$2.3B	$235M	33.9%	14.9%	$340M	—	$126M
Mar '23	$2.3B	$202M	33.1%	13.1%	-$33M	—	$175M
Dec '22	$2.3B	$101M	32.5%	5.8%	$187M	$4.0B	$315M
Sep '22	$2.5B	$256M	34.9%	15.8%	$384M	—	$700M
Jun '22	$2.5B	$234M	34.3%	15.8%	$326M	—	$790M
Mar '22	$2.6B	$355M	37.0%	19.6%	$417M	—	$712M
Dec '21	$2.7B	$390M	37.4%	19.5%	$337M	$4.0B	$872M
Sep '21	$2.8B	$505M	39.8%	23.5%	$472M	—	$987M
Jun '21	$2.5B	$631M	38.6%	20.9%	$376M	—	$560M

Valuation over time

How the market has priced DGX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has risen from 16.6× (Mar '23) to 23.0× (Jun '26).
The price-to-sales ratio has risen from 1.6× (Mar '23) to 2.1× (Jun '26).
The dividend yield has fallen from 1.9% (Mar '23) to 1.5% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is DGX growing its revenue and profit?

Over the past 5 years, Quest Diagnostics's revenue has grown 3.2% per year, and net income declined 7.1% per year. These are computed facts, not advice.

How much debt does DGX have?

As of FY2025, Quest Diagnostics reported $5.7B of total debt against $420M of cash.

What is DGX's profit margin?

In FY2025, gross margin was 33.2%, operating margin 14.1%, and net margin 9.0%.

What is DGX's P/E ratio?

As of Jun '26, Quest Diagnostics traded at a price-to-earnings ratio of about 23.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.